Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

BiDil Articles

Deerfield ups NitroMed unsolicited takeover offer

19 January 2009

Pharma/biotech mergers and acquisitions in 2008

12 January 2009

GSK enters aptamer development deal with Archemix worth up to $1.4B

12 January 2009

NitroMed to sell BiDil business to JHP

3 November 2008

NAACP attacks lack of BiDil Medicare coverage

5 February 2007

FDA confirms no drugs equivalent to BiDil

15 May 2006

US minority coalition to aid pharma access

11 July 2005

US docs back Rx ethnic/racial group targeting

4 July 2005

NitroMed's BiDil closer to US FDA approval

27 June 2005

Study shows genes predict how well diabetes drug will work

26 April 2005

US biotech sector tumbles in July as investors react to choppy market conditions

23 August 2004

NitroMed's BiDil achieves Ph III goals

26 July 2004

NitroMed acquires BiDil NDA for CHF therapy

22 September 1999

Medco/Global Pharm agreement for manufacture of Bidil

31 July 1995

BOEH-MANNHEIM TO SELL MEDCO'S BIDIL

22 November 1993

NitroMed agrees to $36M Deerfield bid

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS